CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 129 enrolled
Drug / intervention
best support care +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04568330
NCT04568330N/ACompleted
CompareCT.gov

Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma

Taipei Veterans General Hospital, Taiwan·interventional·Posted Sep 29, 2020·Updated Sep 29, 2020

In Brief

A clinical study evaluating best support care, moisture cream, and 1 other intervention for Hepatocellular Carcinoma. Completed, enrolled 129 participants.

Detailed Summary

Sorafenib-induced hand-foot skin reaction (HFSR) is a dose-dependent side effect in patients with advance hepatocellular carcinoma (HCC). The appropriate prophylactic dose of urea-based cream and comparison of its effectiveness with other creams remain unclear. The aim of this study was re-validating the prophylactic HFSR incidence density and cutaneous wetness of 10% urea-based cream on sorafenib-induced HFSR in patients with advanced HCC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 29, 2020
Enrollment StartMar 21, 2014
Primary CompletionNov 11, 2015
Study CompletionDec 11, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.8 years ago

Interventions

best support careother

Best support care

moisture creamother

BSC plus moisture cream

10% urea-based creamother

BSC plus 10% urea-based cream.